Innoviva INVA
NASDAQ INVA
$20.55 -0.66 (-3.11%)
At close: Oct 1, 2026 · 4:00 PM EDT

Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026)

Updated

Innoviva (INVA) reported Non-Current Deferred Tax Liability of $36.74 million for Q2 2026, down 49.6% from the prior quarter.

Analysis

Innoviva (INVA) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends

At the end of FY2025, Innoviva posted Non-Current Deferred Tax Liability of $31.79 million.

  • Non-Current Deferred Tax Liability has a three-year compound annual growth rate of 76.6% (FY2022 to FY2025).
  • By year, Non-Current Deferred Tax Liability came in at $563,000 in FY2023 (-90.2%) and $5.77 million in FY2022.
  • Five-year quarterly Non-Current Deferred Tax Liability spans a low of $563,000 in Q4 2023 and a high of $72.83 million in Q1 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Innoviva 1.54 Bn -750.13 Mn 90.62 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 36.74 Mn
Mar 31, 2026 72.83 Mn
Dec 31, 2025 31.79 Mn
Mar 31, 2024 3.81 Mn
Dec 31, 2023 563,000.00
Mar 31, 2023 5.39 Mn
Dec 31, 2022 5.77 Mn
API Access

Innoviva Non-Current Deferred Tax Liability API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deferred-tax-liability&ticker=INVA&period=max&api_key=YOUR_API_KEY